Table 1.
Correlation between clinicopathological factors and survival of the 133 patients.
Figure 1.
Survival curves of the whole population and subgroups according to prognostic factors.
(A) Overall survival curve of the total 133 patients. (B) Survival curves of the patients with or without ascites. (C) Survival curves of the patients who had or hadn’t undergone gastrectomy. (D) Survival curves of the patients with or without ascites in the subgroup of 89 patients who underwent gastrectomy. (E) Survival curves of the patients had or hadn’t undergone gastrectomy in the subgroup of 69 patients with synchronous ovarian metastasis. (F) Survival curves of patients who underwent gastrectomy and without ascites or patients who hadn’t undergone gastrectomy and with ascites.
Table 2.
Correlation between expressions of CSCs related proteins and survival.
Figure 2.
Expressions of three CSCs related molecules in paraffin sections of ovarian metastases.
A representative figure of positive (upper panel) or negative (lower panel) expression of (A) CD44, (B) CD133, and (C) Sox2 detected by IHC as described in experimental procedures (original magnification,×200).
Figure 3.
Expressions of three CSCs related molecules in ovarian metastases correlated with patients’ survival.
(A) Survival curves of patients with positive or negative expression of CD44. (B) Survival curves of patients with positive or negative expression of CD133. (C) Survival curves of patients with positive or negative expression of SOX2.
Table 3.
Correlation between CSCs related proteins expressions and clinicopathological characteristics.